Delcath Systems (DCTH) to Post Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Delcath Systems to announce earnings of ($0.09) per share and revenue of $26.2590 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. The firm had revenue of $24.99 million for the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Delcath Systems Price Performance

Shares of Delcath Systems stock opened at $13.04 on Tuesday. The company has a 50-day moving average of $12.10 and a 200 day moving average of $10.77. The firm has a market cap of $450.14 million, a price-to-earnings ratio of 1,304.00 and a beta of 0.52. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $13.74.

Institutional Trading of Delcath Systems

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd raised its holdings in Delcath Systems by 339.4% in the fourth quarter. XTX Topco Ltd now owns 71,193 shares of the company’s stock worth $719,000 after buying an additional 54,990 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Delcath Systems by 3.0% during the fourth quarter. Millennium Management LLC now owns 246,444 shares of the company’s stock valued at $2,489,000 after buying an additional 7,190 shares during the last quarter. Man Group plc grew its holdings in shares of Delcath Systems by 34.1% during the fourth quarter. Man Group plc now owns 38,158 shares of the company’s stock valued at $385,000 after buying an additional 9,705 shares during the last quarter. Balyasny Asset Management L.P. increased its position in shares of Delcath Systems by 69.5% during the fourth quarter. Balyasny Asset Management L.P. now owns 52,140 shares of the company’s stock valued at $527,000 after acquiring an additional 21,384 shares in the last quarter. Finally, Jump Financial LLC increased its position in shares of Delcath Systems by 68.0% during the fourth quarter. Jump Financial LLC now owns 45,953 shares of the company’s stock valued at $464,000 after acquiring an additional 18,596 shares in the last quarter. 61.12% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on DCTH shares. Zacks Research upgraded shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. BTIG Research reiterated a “buy” rating and set a $17.00 target price on shares of Delcath Systems in a report on Monday, July 13th. Finally, Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.17.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.